Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Translating Fatigue to Human Performance.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
FDA denies Teva Copaxone generic trials petition
RILUTEK®
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Mitoxantrone-induced suicidal erythrocyte death.
Fingolimod is a potential novel therapy for multiple sclerosis.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.

Pages